No Data
Memo for next week.
On November 11 (Monday), the holiday markets in the USA, France, and Canada are closed. Reserve Bank of New Zealand's fourth-quarter inflation expectations for the next two years: previous value 2.03%. Japan's October banks (including trusts) lending rate: previous value increased by 2.7%. Japan's September trade account: predicted deficit of 66.2 billion yen; previous deficit of 377.9 billion yen. Japan's September current account: predicted surplus of 3.4327 trillion yen; previous surplus of 3.8036 trillion yen. Japan's October economic observers' current situation index: predicted 47.1; previous value 47.8. Japan's October economic observers' future outlook index: predicted 49.2; previous value 49.7.
Lu Chongmao: The "1+" mechanism has approved a total of 5 new drug applications, with the cost of 2 drugs decreasing by nearly 30%.
Dr. Constance Chan, Director of Health, stated at the Legislative Council meeting today (8th) that since the new drug approval mechanism ("1+1" mechanism) took effect, the Department of Health has received inquiries from more than 80 pharmaceutical companies, totaling over 260, and has approved a total of 5 new drug applications. These include 2 treatments for metastatic colorectal cancer, 1 treatment for paroxysmal nocturnal hemoglobinuria, 2 treatments for patients with parathyroid cancer and a certain type of hypercalcemia in patients with primary hyperparathyroidism. Dr. Constance Chan revealed that two of the new drugs for the treatment of metastatic colorectal cancer have been included in the public hospital authority's list of specialty drugs. The public hospital authority has also successfully completed procurement discussions.
Hong Kong stocks have seen unusual movements, with CRO concept stocks generally under pressure. The emotions are influenced by the results of the USA election. Institutions point out that the probability of the Biosecurity Law being an independent law may
CRO concept stocks are generally under pressure. As of the time of publication, GenScript Biotech (01548) fell by 6.68% to HKD 10.9; Viva Biotech (01873) fell by 3.16% to HKD 0.92; Pharmaron (03759) fell by 2.64% to HKD 16.22.
Express News | CSPC Innovation Pharmaceutical: The controlling shareholder intends to increase shareholding by 0.1 billion yuan to -0.12 billion yuan.
cspc pharma (01093.HK) will hold a board of directors meeting on November 15th to approve the performance of the first three quarters.
Gelonghui November 5th, CSPC Pharma (01093.HK) released an announcement that the board of directors' meeting will be held on November 15, 2024, to approve the unaudited comprehensive performance announcement of the company and its subsidiaries for the nine months ended September 30, 2024.
CSPC PHARMA: DATE OF BOARD MEETING
No Data
No Data